Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

The investigators previously developed CD19-targeted ET019003 T cells by fusing the Fab fragment with γ/δ TCR constant chain plus adding a co-stimulatory molecule. Among 12 treated patients enrolled in the phase I clinical trial (NCT03642496), 6 achieved complete remission and no serious adverse events were observed, demonstrating that ET019003 T cells are both safe and effective. However, its efficacy is limited in patients with loss of CD19 expression. To overcome tumor immune escape driven by antigen loss, investigators designed the novel AbTCR-T cells simultaneously targeting CD19 and CD22. This trial is conducted to explore the safety and efficacy of AbTCR (anti-CD19/CD22)-T cells in treating patients with refractory/relapsed aggressive lymphomas.